Quarterly report Q2 2024

The information was provided for publication on August 28, 2024.

PROLIGHT
Diagnostics you can count on

TABLE OF CONTENTS



Second quarter, April 1 - June 30, Q2 2024 Group

(figures in parentheses refer to the corresponding period in the previous year)

- Net sales amounted to 0 (0).
- Other operating income amounted to SEK 18 (101) thousand.
- The profit after tax amounted to SEK -11,224 (-8,033) thousand.
- Earnings per share before and after dilution: -0.02 (-0.03) SEK.
- Cash flow from current operations was SEK -88 (-8,571) thousand.

Second half-year, January 1 - June 30, Q2 2024 Group

(figures in parentheses refer to the corresponding period in the previous year)

- Net sales amounted to 0 (0).
- Other operating income amounted to SEK 86 thousand (140).
- The profit after tax amounted to SEK -20,152 (-15,613) thousand.
- Earnings per share: -0.04 (-0.06) SEK.
- Cash flow from current operations was SEK -8,888 (-13,972) thousand.

Product in development phase. Design and specification may change in the final product.

Significant events during the quarter

- Capitalized development costs for troponin testing with the MicroFlex POC system were written down by SEK 113 million.
- A positive accounting adjustment of SEK 5.6 million for the full year 2023 was announced.
- The cartridge design for Psyros for commercial use was completed.
- MDx CRO was appointed to perform clinical validation studies with the POC system Psyros, for high sensitive troponin testing.
- A British government grant of SEK 17 million was received in collaboration with a leading British hospital association. The funds will be used, among other things, for a pre-validation study at St Thomas' Hospital in London, which was initiated during the quarter.
- At the Annual General Meeting on May 27, Masoud Khayyami, Maria Holmlund, Ulf Bladin, Steve Ross, Aileen McGettrick, and Tobias Volker were re-elected as board members, and Kiarash Farr was newly elected. Masoud Khayyami was re-elected as Chairman of the Board.
- The series TO6 warrant program raised approximately SEK 9.8 million before issuance costs. The board and management excercised their options in full.

Significant events after the end of the period

- The Psyros system was showcased at DxPx during the major international ADLM congress in Chicago from July 28 to August 1, 2024.

Financial calendar

November 27, 2024
Interim Report Q3

February 21, 2025
Year-End Report 2024

April 21, 2025
Annual Report 2024

May 14, 2025
Interim Report Q1

August 28, 2025
Interim Report Q2

CEO statement

"In Chicago, we observed even greater interest from major diagnostic companies than in previous years, consistently receiving very positive feedback from potential customers and partners.

During the second quarter, we continued to advance our unique digital POC platform, Psyros, towards market approval quickly and cost-effectively.

Our plan is to further develop and refine our platform into a commercial POC system, with readiness for a clinical performance study scheduled for 2025. Our POC system will focus on the rapid rule-in or rule-out of myocardial infarction by quantifying individual molecules of the protein troponin, down to single-digit nanograms per liter (ng/L).

In close collaboration with ITL (Integrated Technologies Limited) and G&H Group, we have been working during the second quarter to produce the final components needed to begin the production of beta prototypes for the instrument. These prototypes are scheduled for testing, evaluation, and verification of regulatory compliance in the autumn. Additionally, in partnership with Flex Medical Solutions, our supplier for the disposable cartridge, we have finalized the design of the cartridge intended for commercial use. The design's simplicity not only ensures a highly competitive cost but also facilitates the outsourcing of manufacturing.

The cartridge is composed of only a few components, optimized for large-scale manufacturing to achieve a competitively low production cost. A key competitive advantage is that it includes all necessary reagents for the test, eliminating the need for complex and expensive liquid reagents and blister packs. Additionally, the cartridge is ergonomically designed for ease of use and is compatible with venous and capillary blood as well as plasma samples.

Another significant advantage is its multiplex capability, allowing for the measurement of multiple biomarkers on a single cartridge using just a drop of blood.

In collaboration with renowned institutions, including St. Thomas' Hospital in London, we were awarded a prestigious SEK 17 million grant from the British i4i (Invention for Innovation) program during the quarter. This grant will enable us to initiate a study using whole blood samples from patients presenting at St. Thomas' Hospital with chest pain and suspected heart attacks. Additionally, a substantial number of blood samples will be tested on our platform, utilizing a biobank of blood from patients with chest pain, confirmed myocardial infarctions, and healthy individuals, to validate the test and prototype performance of the Psyros system. Initial data from patient samples will be generated in the fall, with the first results expected in the fourth quarter of 2024. The insights gained from this study will be instrumental in the final optimization of both the test and the platform, ensuring high confidence before the clinical validation study. We expect that these results will further increase the interest of potential industrial partners.

Our latest whole blood troponin data confirm that we are ready to begin testing with patient samples. The data generated using the final commercial cartridge design meets the stringent requirements for single-point rule-out and the measurement of delta values for risk stratification in patients presenting with symptoms of myocardial infarction. With these promising results, we are now prepared to initiate the pre-validation study on both stored and fresh clinical samples, as we gear up for the clinical validation study. This study, to be conducted by the MDx CRO, is scheduled to begin as a multicenter trial in early 2025. The outcomes will provide the basis for a regulatory application, paving the way for our planned commercial launch in early 2026.

I would like to take this opportunity to thank both our long-standing and new shareholders for the trust they placed in us through the warrant program completed in May. The exercise of warrants from series TO6 has brought approximately SEK 9.8 million to the company before issuance costs.

Both the board and management exercised their options in full, and I am pleased to report that the total shareholding of the management and board also increased during the first half of 2024.

Our achievements to date have demonstrated that our system has the potential to become the first digital, ultra-sensitive, portable platform for near-patient testing of high-sensitivity troponin. The system's ease of use and low production costs align perfectly with market needs. This was validated at the recent international ADLM (American Association for Clinical Chemistry) congress in Chicago, which attracted over 20,000 participants from around the globe. Prolight showcased its latest instrument prototype and commercial disposable cartridge at our own stand. Images of these can be found in this report and on our website.

Additionally, our digital platform Psyros was prominently featured at the stands of our partners ITL/G&H-group and Flex Medical, resulting in significant exposure throughout the congress.

The MicroFlex platform was also presented at TTP's stand, where it generated considerable interest.

The interest in Psyros at this year's congress surpassed previous years due to the rapid and successful development of the system. As a result, we had significantly more individual meetings with leading global diagnostic companies than ever before. Our list of high-potential partners is now longer than it has been in the past, and we will be scheduling follow-up meetings with several of these prospects. A key aspect of these discussions will be the results of the pre-validation study, which we anticipate receiving by the end of this year. We expect that these results will further boost interest in our digital platform. I look forward to updating you on our progress.

Lund August 28th 2024

Ulf Bladin
CEO Prolight Diagnostics (publ)

During the ADLM congress, COO Karl Bullen, CEO Ulf Bladin and CTO Steve Ross participated.

Safe point-of-care tests enable faster diagnoses

Prolight Diagnostics has, over a long period, experienced a sharply increasing demand in the market for user-friendly and near-patient analysis systems, so-called Point-of-Care ("POC") systems. A couple of examples are the mergers and acquisitions that have taken place. For example, Roche's acquisition of LumiraDx for 295 MUSD last year and Biomerieux's purchase of Specific Diagnostics for 417 MUSD the year before. Additionally, Thermo Fisher Scientific's acquisition of Mesa BioTech in 2021 for USD 450 million and Abbott's acquisition of Alere for USD 5.8 billion already in 2016 show the greatly increased interest.

Primary and elderly care, emergency departments and ambulances demand fast, reliable blood test results when the patient is first examined instead of being forced to submit blood samples to hospital laboratories and wait hours or days for results, which is currently the case. Access to point-ofcare analyses is especially important in acute conditions, such as for patients exhibiting acute chest pain and suspected myocardial infarction. In these situations, it is critical to make an early and correct diagnosis and initiate adequate treatment to save lives.

To meet this demand, Prolight is developing a new and flexible POC system, Psyros™, which can perform In-Vitro Diagnostic ("IVD") tests with the same sensitivity and precision as hospital laboratories but with the difference that test results can be given already within ten minutes. By obtaining these test results early in the patient care continuum, doctors and healthcare professionals can make the correct diagnosis and prioritise adequate resources for the right patient. As a result, substantial cost savings can also be realised in the heavily burdened healthcare system.

The new digital immunoassay technology was incorporated into Prolight in early 2022 through the acquisition of the British company Psyros Diagnostics Ltd (Psyros), which has developed a new, cutting-edge POC technology for digital immunoassay. The wholly owned subsidiary Psyros Diagnostics currently has a highly competent team with long and broad experience in In Vitro Diagnostic (IVD) development, especially in POC tests and POC systems.

The team has unique competencies and experiences vital to the company's continued development.

Prolight's pioneering POC technology counts individual molecules digitally from a drop of blood. This proprietary technology, which also has the possibility of multiplexing (testing several biomarkers at the same time), enables the measurement of biomarkers with extremely low detection levels (femtomolar 10-15) within approximately 10 minutes or less. To Prolight's knowledge, there is no other existing digital POC system deemed capable of performing these analyzes at extremely low concentrations with such simplicity, precision, and low production costs. The system consists of an easy-to-use cartridge and a portable analysis unit. Only a drop of blood is required to perform the test.

The cutting-edge technology will first be used to develop a diagnostic POC test that measures the protein troponin with high sensitivity and accuracy, to aid in the rule-in and rule-out of myocardial infarction. By measuring the biomarker troponin, which is released from the heart into the bloodstream during the acute phase of myocardial infarction, the test helps to make a rapid diagnosis. Elevated levels of the protein troponin in the blood are a sign of damage in the heart muscle cells. The test places great demands on sensitivity and precision and has a substantial global sales potential.

The technology also opens up the possibilities of being able to develop new POC tests in a number of different clinical areas that were previously only possible to carry out in specialized laboratories. Prolight has been able to demonstrate that its digital high-sensitivity immunoassay can measure low levels of specific proteins down to single-digit nanograms per liter (ng/L) with laboratory-grade reproducibility. These concentrations are indicative of what is required to rule out myocardial infarction with high-sensitivity troponin assays[1].

These proof-of-performance results were obtained partly in November 2022 by measuring the levels of thyroid-stimulating hormone (TSH) in human plasma samples, partly in June 2023 by measuring high-sensitivity troponin in serum samples, and also

[1] European Cardiology Society´s Guidelines on Fourth Universal Definition of Myocardial infarction.

in November 2023 when the company was able to show that the system for detecting single molecules provides equivalent performance in whole blood compared to plasma, without the need to separate the cells from the sample. This reduces complexity and paves the way for an extremely competitive price level. The development work focuses on continued development of the unique POC technology for digital immunoanalysis.

This development work includes developing prototype systems for instruments and cartridges, carrying out sensitivity analyses, developing a commercial system for verification and validation studies, developing test card manufacturing, starting a clinical validation study, compiling regulatory documentation to then be able to start the registration process in Europe,followed by the USA.

Vision & Strategy

Vision

Prolight Diagnostics develops pioneering, innovative Point-Of-Care (POC) systems, for quick and reliable diagnosis of acute events, initially for myocardial infarction.

We offer our innovative POC systems to companies with global sales organisations in relevant POC segments.

Strategy

With Prolight's POC system, the ambition is to have test results available to doctors within ten minutes to allow rapid diagnosis and treatment when the patient is examined the first time, instead of spending critical time waiting for results from a hospital laboratory. This could be, for example, in an emergency department, a healthcare centre, an ambulance, or a care home.The ability to rule-in or rule-out myocardial infarction early in the care pathway will contribute to an efficient treatment for the right patients, allowing significant cost savings.

Initially, the focus will be on the measurement of the cardiac biomarker troponin, with high sensitivity and precision, which has a substantial global sales potential. The intention is also to include more biomarkers on the company's platform if they are deemed to be strategically and economically beneficial.

We are open to discussions about partnerships with relevant companies in the POC market.

[1] European Cardiology Society´s Guidelines on Fourth Universal Definition of Myocardial infarction.

Point-of-Care

Point of Care – a rapidly growing global market

There is an acute awareness of the value of rapid, accurate, and efficient testing near the patient. The market demands that more tests are moved out from large hospital laboratories and closer to the patient and care giver. POC tests can also help reduce healthcare costs by giving faster results and more rapid treatment. Throughout the Covid pandemic, the use of POC testing increased substantially. This led to an acute awareness of the value of rapid, simple, and efficient testing near the patient. Most companies, healthcare providers, politicians and the general public realize the value of these tests, benefitting patients, clinicians, and healthcare in general. This interest has, in turn, created a need for new technologies that can meet the challenges of more demanding tests, whilst still being competitively priced.

According to Fortune Business Insights, the POC market is expected to grow from USD 45.85 billion in 2023 to USD 78.11 billion in 2030[2].

The global market for cardiac biomarkers
The global market for cardiac biomarkers was approximately USD $9.0 billion in 2021 and is expected to grow by approximately 9 percent per year until 2027. Thus, the estimated global market for cardiac biomarkers is expected to amount to approximately USD $14.9 billion in 2027[3].

POC testing for cardiac biomarkers is driven by an increase in global heart disease, coupled with increased awareness about the utility of early diagnosis, in order to provide the most effective treatment for patients.

Trends favoring the market development of POC tests
The main driving forces behind the general growth of POC tests, in addition to the covid pandemic, are considered to be increased need for diagnostics in developing countries, increased demand for central laboratory tests that are moved to clinics closer to the patient, e.g. primary care and nursing homes, rapid technical development, digitization within healthcare, increasing investments in research and development as well as an ageing population in the West.

[2] https://www.fortunebusinessinsights.com/industry-reports/point-of-care-diagnostics-market-101072

[3] IMARC Group, Cardiac Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and forecast 2022-2027, december 2021

Groundbreaking technology

Prolight is poised to deliver the most innovative and best-in-class POC systems on the market

Prolight is well-positioned to deliver POC systems to satisfy several clinical unmet needs. These include high sensitivity troponin, other biomarkers currently not available at POC and multiplex assays for measuring several analytes simultaneously.

A new ground-breaking POC technology for digital immunoassay
Through the acquisition of Psyros, Prolight now has an entirely novel cutting-edge POC technology for digital immunoassay, which can count individual molecules from a single drop of blood. The unique technology opens the possibility of developing new POC tests in a wide range of clinical areas that were previously only possible in specialised laboratories. Further advantages of the digital immunoassay include its simplicity and low production costs.

Detection limit at the level of PCR tests, but with significantly faster response time
Today, PCR tests are recommended to confirm Covid, but the response time is lengthy, sometimes several hours to days, depending on the system. By using our digital assay technology, it is possible to count individual molecules at low levels, including viral particle proteins, such as coronavirus. As a result, sensitivity and accuracy can be as good or better than PCR tests currently offered on large central laboratory instruments. The large and highly significant difference between today's PCR tests and Prolight's innovative digital POC platform is that the response time can be reduced to just ten minutes or less.

May be the start of a paradigm shift in POC testing
This novel technology could mark the beginning of a paradigm shift in POC testing for clinical diagnostics. Some examples of possible future clinical areas are: Neuropathology (dementia, traumatic brain injuries), Immune system dysfunction (sepsis, autoimmune diseases), Rapid virus detection such as Covid. The unique technology behind the digital immunoassay will make it possible to test a range of biomarkers with high sensitivity and accuracy on a single POC instrument. Prolight believes that this technology could be a paradigm shift in POC testing for clinical diagnostics.

Prolight has a strong patent portfolio

The patent situation for the digital immunoassay, Psyros™
For the digital immunoassay, PsyrosTM, five patent applications are filed. The first two applications have completed the PCT phase and are now being pursued in different territories worldwide. The third application is in the PCT phase. The fourth application covers various aspects of multiplexing (i.e., detecting several different biomarkers at the same time on a single sample). By using Prolight's unique single molecule counting technology, multiplexing can be carried out in a single drop of blood on a sensor without needing to split the sample into separate areas.

The fifth application uses a similar approach to allow the measurement of the same biomarker at both very low and very high concentrations simultaneously. The benefit of the unique technology is that the sample size remains extremely small, and that the sensor is easy to manufacture, yet also offering the ability to detect very low concentrations of biomarkers with high specificity. The last two patent applications have been submitted to the Intellectual Property Office in Great Britain and are now in the PCT phase.

The patent situation for MicroFlex
For MicroFlex, the patent portfolio consists of four granted patents (two in the US, one in the EU, and one in Sweden), along with four patent applications, the latest of which was filed in 2020. One of the patent applications concerns how the sampling tube can be directly integrated into the cartridge. Another patent application concerns cartridge containing an integrated centrifuge. This makes for a straightforward workflow for any clinical environment. No trained personnel are needed to pipette and centrifuge the blood sample. MicroFlex thereby creates the conditions to offer a fully automated platform for immunodiagnostics. Two of the patent applications have progressed to the national phase and are now being pursued in different territories, while the others are in the PCT phase.

About PCT and patent application processe
Patent Cooperation Treaty (PCT) is an international agreement that allows you to obtain, with a single application, in one language, a novelty search and preliminary patentability assessment conducted by one authority for approximately 150 countries. For a PCT application to lead to a patent in a particular country (or territory, such as the EU), the application must be prosecuted at the respective patent office.

During the patent application process, it is normal for the reviewing authority to ask several questions, which Prolight and the company's legal representatives spend much time answering to achieve the strongest possible patent protection. This correspondence takes different amounts of time depending on each authority's questions. It is, therefore, challenging to give an exact date for when an individual patent application can be expected to be approved.

Owners

Owners list as of 2024-06-28

	Holdings 2024-06-28	Votes in %
FÖRSÄKRINGSAKTIEBOLAGET AVANZA PENSION	34 207 313	5,73
AILEEN JANE MCGETTRICK	31 505 100	5,27
JULIE RICHARDS	31 505 100	5,27
PAUL BRENDAN MONAGAN	31 505 100	5,27
STEVEN ANDREW ROSS	31 505 100	5,27
NORDIC UNDERWRITING APS	21 296 928	3,57
THE BANK OF NEW YORK MELLON, W9*	11 253 728	1,88
TUVEDALEN LIMITED	10 390 956	1,74
CARDEON AB (PUBL)	9 350 000	1,57
JAN KARLSSON	5 884 180	0,99
Total, 10 largest owners	218 403 505	36,57
Other	378 883 600	63,43
Total	597 287 105	100,0

The shareholder list indicates the holding of shares in Prolight as of June 28, 2024 and does not include Paid Subscription Units ("BTU") subscribed to in the company's rights issue that was carried out in December 2023.

* Refers to the technology and development partner's ownership (TTP, via management structure).

The company has outstanding warrants for management and board of 2,500,000 and employees of Psyros Diagnostics Ltd. of 5,370,000, which can result in a total of 7,870,000 shares and can thus cause dilution. As of January 2024, the company has outstanding warrants series TO7 of 108,756,747 options.

Prolight Diagnostics' share is traded on the Nordic Growth Market, NGM SME, under the name PRLD.

Source: Euroclear

The group's development during quarter 2, 1 April to 30 June 2024

(figures in parentheses refer to the corresponding period in the previous year)

INCOME

- During product development, the Prolight group lacks sales and net sales.
- Other income for the period amounted to SEK 17,985 (100,559), mainly consists of exchange rate gains and distribution income from NGM.

COSTS AND RESULTS

- The Prolight Group's total operating costs during the period amounted to SEK 15,318,687 (11,116,833) and the increase mainly consists of external costs and personnel costs linked to the development of the Group's products.
- Capitalized work for own account amounted to SEK 4,140,433 (3,048,746) and refers to costs for the group's product development in Psyros Diagnostics Ltd.

FINANCING AND CASH FLOW

- Cash flow from current operations amounted to SEK -88,088 (-8,570,865).
- The Prolight Group's cash flow from investment activities amounted to SEK -8,119,969 (-3,928,985) and in the period consists mainly of capitalized development costs of SEK 4,140,433 (3,048,746) linked to the group's product development.
- The total cash flow for the period was SEK 1,072,165 (-12,499,850). The period's cash flow includes a new issue of SEK 9,280,222.

The group's development during the first half of the year, 1 January to 30 June 2024

(figures in parentheses refer to the corresponding period in the previous year)

INCOME

- During product development, the Prolight group lacks sales and net sales.
- Other income for the period amounted to SEK 86,481 (139,866), mainly consists of exchange rate gains and distribution income from NGM.

COSTS AND RESULTS

- The Prolight Group's total operating costs during the period amounted to SEK 27,585,303 (22,190,898) and the increase mainly consists of external costs and personnel costs linked to the development of the Group's products.
- Capitalized work for own account amounted to SEK 7,470,804 (6,503,598) and refers to costs for the group's product development.

FINANCING AND CASH FLOW

- Cash flow from current operations amounted to SEK -8,887,607 (-13,972,471).
- The Prolight Group's cash flow from investment activities amounted to -11,956,491 SEK (-8,880,600) and in the period consists primarily of capitalized development costs of -7,470,804 SEK (-6,503,598) linked to the group's product development.
- The total cash flow for the period was SEK 19,485,248 (-22,853,071). The period's cash flow includes a new issue of SEK 40,329,346.
- Cash and cash equivalents for the group as of 30 June 2024 were SEK 32,395,735 (31,676,036).

EQUITY, RECEIVABLES AND LIABILITIES

(numbers in brackets refer to 2023-12-31)

- Equity in the group amounted to SEK 122,276,285 as of June 30, 2024 (132,992,378).
- Provisions amounted to 17,791,558 (17,791,558) and consist of a deferred tax liability regarding the acquired technology platform in Psyros Diagnostics Ltd.
- Short-term receivables amounted to SEK 3,108,127 (9,580,221).
- Short-term liabilities amounted to SEK 22,588,355 (18,449,380). The majority of approximately SEK 13 million consists of a debt to the former owners of Psyros Diagnostics Ltd for an assessed additional purchase price.
- The total assets as of June 30, 2024 amounted to SEK 162,656,198 (169,233,316) and mainly consists of acquired intangible fixed assets of SEK 86,237,658 (85,922,459) which relate to the technology platform in Psyros Diagnostics Ltd. and intangible fixed assets of 34,033,440 (26,564,642) which refer to capitalized work for own account.
- The equity ratio was 75 percent (79)

The parent company's development during quarter 2, April 1 – June 30, 2024

(figures in parentheses refer to the corresponding period in the previous year)

INCOME

- During the time of product development, Prolight lacks sales and net sales, this was also the case during the comparison period.
- Other income for the period amounted to SEK 1,037,985 (1,120,559) and mainly consisted of invoiced costs to Psyros for business management services, exchange rate gains and distribution income from NGM.

COSTS AND RESULTS

- Prolight's total operating costs during the period amounted to SEK 2,367,459 (2,629,794) and mainly consisted of external costs relating to consulting costs for business management services.
- The financial net was SEK 81 (73).
- The result for the quarter amounted to SEK -1,329,394 (-1,509,162).

FINANCING AND CASH FLOW

- Cash flow from current operations amounted to - SEK 11,138,832 (-14,940,256).
- The total cash flow for the quarter was SEK -1,858,520 (-14,940,256). The period's total cash flow includes a new issue of SEK 9,280,312.

The parent company's development during the first half of the year 1 January - 30 June 2024

(figures in parentheses refer to the corresponding period in the previous year)

INCOME

- During the time of product development, Prolight lacks sales and net sales, this was also the case during the comparison period.
- Other income for the period amounted to SEK 2,126,481 (2,179,866) and mainly consisted of invoiced costs to Psyros for business management services, exchange rate gains and distribution income from NGM.

COSTS AND RESULTS

- Prolight's total operating costs during the period amounted to SEK 4,468,959 (5,007,006) and mainly consisted of external costs relating to consulting costs for business management services.
- The financial net was SEK 2,179 (-154).
- The result for the half year amounted to SEK -2,340,299 (-2,826,987).

FINANCING AND CASH FLOW

- Cash flow from current operations amounted to SEK -23,943,817 (-20,972,116).
- The total cash flow for the half year was SEK 16,385,529 (-20,972,116). The period's total cash flow includes a new issue of SEK 40,329,346.
- Cash and cash equivalents as of 30 June 2024 were SEK 25,653,676 (24,578,686).

EQUITY, RECEIVABLES AND LIABILITIES

(numbers in brackets refer to 2023-12-31)

- Equity as of 30 June 2024 amounted to SEK 103,036,039 (96,244,423).
- Short-term receivables amounted to SEK 21,463,839 (500,335) and short-term liabilities to SEK 14,685,095 (15,325,108), of which SEK 13,000,003 (13,000,003) and which consists of a debt to the former owners of Psyros Diagnostics Ltd for an assessed additional purchase price.
- The total assets as of 30 June 2024 amounted to SEK 117,721,133 (111,569,531) and mainly consists of intangible fixed assets which at the end of the period amounted to 1,835,958 (1,835,958) and shares in Psyros Diagnostics Ltd of SEK 68,767,661 (68,767,661).
- The equity ratio was 88 percent (86).

Other information

RISKS AND UNCERTAINTIES
Prolight Diagnostics' operations are exposed to a number of risks and uncertainty factors, which to varying extents can have a negative impact on continued operations. Both external, operational and finance-related risks can negatively affect the company in the short and long term. Prolight works continuously to inventory and manage the risks and uncertainty factors that the business is exposed to in order to limit risk exposure and any impact if a risk materializes. A detailed description of risks and risk management can be found in the annual report for 2023.

ACCOUNTING PRINCIPLES
This interim report has been prepared in accordance with Chapter 9 of the Annual Accounts Act. Prolight applies the Accounting Board's general advice 2012:1 (K3) when preparing the company's financial reports.

AUDITOR'S REVIEW
The quarterly report has not been subject to an auditor's review.

TRANSACTIONS WITH RELATED PARTIES
No significant transactions with related parties have been carried out during the period except with the company's CEO. The transactions have taken place on market terms.

MISCELLANEOUS
The company has outstanding warrants to management and the board of 2,500,000 and to employees of Psyros Diagnostics Ltd. about 5,370,000, which can result in a total of 7,870,000 shares and can thus cause dilution. As of January 2024, the company has outstanding warrants series TO7 about 108,756,747 options.

Prolight Diagnostics' share is traded on the Nordic Growth Market, NGM SME, under the name PRLD.

GROUP FINANCIAL STATEMENTS

Income Statement, summary Group

Amount in SEK	Apr-Jun		Jan-Jun		Full Year
	2024	2023	2024	2023	2023
Net Sales	**0**	**0**	**0**	**0**	**0**
Activated work for own account	4 140 433	3 048 746	7 470 804	6 503 598	12 574 638
Other income	17 985	100 559	86 481	139 866	11 748 113
Operating expenses					
Other external costs	-10 236 815	-8 130 322	-18 120 433	-16 939 368	-30 738 665
Personnel costs	-4 767 558	-2 822 600	-8 933 033	-4 937 226	-15 204 741
Depreciation	-311 576	-171 550	-523 038	-299 310	-775 245
Write-down intangible assets	0	0	0	0	-113 300 014
Other operating expenses	-2 738	7 639	-8 798	-14 994	-122 844
Total expenses	**-15 318 687**	**-11 116 833**	**-27 585 303**	**-22 190 898**	**-160 141 509**
Operating result	**-11 160 269**	**-7 967 528**	**-20 028 017**	**-15 547 434**	**-135 818 758**
Result from financial investments					
Other interest income and similar items	81	73	2 179	154	546 346
Other interest expenses and similar items	-63 388	-65 249	-126 464	-65 249	-189 009
Total result from financial investments	**-63 307**	**-65 176**	**-124 285**	**-65 095**	**357 337**
Net loss	**-11 223 576**	**-8 032 704**	**-20 152 302**	**-15 612 529**	**-135 461 421**

Balance Sheet, summary Group

Amount in SEK	2024-06-30	2023-06-30	2023-12-31
ASSETS			
Assets	**0**	**0**	**31 197 429**
Fixed assets			
Acquired intangible assets	86 237 658	85 900 245	85 922 459
Capitalized expenditure on development work and similar work	34 033 440	133 799 326	26 564 642
Equipment, tools, fixtures and fittings	6 881 238	2 982 127	2 694 278
Total fixed assets	*127 152 336*	*222 681 697*	*115 181 379*
Current assets			
Other receivables	3 034 524	1 949 350	9 422 196
Tax receivables	4 165	4 165	0
Prepaid expenses and accrued income	69 438	84 022	158 025
Cash and cash equivalents	32 395 735	31 676 036	13 274 287
Total current assets	*35 503 863*	*33 713 573*	*22 854 508*
Total assets	**162 656 198**	**256 395 271**	**169 233 316**
Equity			
Share capital	59 728 710	28 226 945	34 682 296
Other paid in capital	236 350 649	195 603 686	252 265 149
Retained eranings	-153 650 771	-19 005 455	-18 493 646
Loss in the period	-20 152 302	-15 612 529	-135 461 421
Total equity	*122 276 285*	*189 212 647*	*132 992 378*
Provisions			
Additional purchase price for subsidiaries	0	45 098 707	0
Accrued tax liabilities	17 791 558	17 791 558	17 791 558
Total Provisions	*17 791 558*	*62 890 265*	*17 791 558*
Current liabilities			
Accounts payables	7 905 680	2 915 897	4 175 528
Other liabilities	13 633 087	395 938	13 316 896
Accrued expenses and deferred income	1 049 588	980 524	956 956
Total current liabilities	*22 588 355*	*4 292 359*	*18 449 380*
Total equity and liabilities	**162 656 198**	**256 395 271**	**169 233 316**

Changes in shareholders equity, Group

Amount in SEK	Share capital	New share issue in progress	Other paid in capital	Other capital incl result for the period	Total shareholders equity
Shareholders equity 2024-01-01	**34 682 296**	**15 038 855**	**237 226 294**	**-153 955 067**	**132 992 378**
Issue of new shares	25 046 414	-15 038 855	642 857		10 650 416
New share issue in progress					0
Issuance cost			-1 518 501		-1 518 501
Loss for the period				-20 152 302	-20 152 302
Foreign exchange rate adjustment				304 294	304 294
Shareholders equity 2024-06-30	**59 728 710**	**0**	**236 350 649**	**-173 803 075**	**122 276 285**

Amount in SEK	Share capital	New share issue in progress	Other paid in capital	Other capital incl result for the period	Total shareholders equity
Shareholders equity 2023-01-01	**28 226 945**	**0**	**195 603 686**	**-18 425 593**	**205 405 038**
Issue of new shares	6 455 351		16 138 378		22 593 729
New share issue in progress		15 038 855	37 597 139		52 635 994
Issuance cost			-12 112 909		-12 112 909
Loss for the period				-135 461 421	-135 461 421
Foreign exchange rate adjustment				-68 053	-68 053
Shareholders equity 2023-12-31	**34 682 296**	**15 038 855**	**237 226 294**	**-153 955 067**	**132 992 378**

Cash flow statement, Group

Amount in SEK	Apr-Jun		Jan-Jun		Full Year
	2024	2023	2024	2023	2023
OPERATING ACTIVITIES					
Profit after financial items	-11 223 576	-8 032 703	-20 152 302	-15 612 529	-135 272 689
Adjustment	374 924	-963 725	649 462	-836 700	114 075 759
Cashflow from operating activities before changes in working capital	*-10 848 653*	*-8 996 428*	*-19 502 840*	*-16 449 229*	*-21 196 930*
Cash flow from changes in working capital					
Changes in receivables	6 076 005	184 670	6 476 259	692 427	-6 860 748
Changes in liablilites	4 684 559	240 893	4 138 975	1 784 331	3 509 279
Total Cash flow from changes in working capital	*10 760 565*	*425 563*	*10 615 233*	*2 476 758*	*-3 351 469*
Cash flow from operating activities	**-88 088**	**-8 570 865**	**-8 887 607**	**-13 972 471**	**-24 548 399**
INVESTMENT ACTIVITIES					
Investment in intangible assets	-4 140 433	-3 048 746	-7 470 804	-6 503 598	-12 574 638
Investment in tangible assets	-3 979 536	-880 239	-4 485 687	-2 377 002	-2 804 065
Cash flow from investment activities	**-8 119 969**	**-3 928 985**	**-11 956 491**	**-8 880 600**	**-15 378 703**
FINANCING ACTIVITIES					
Share issue	9 750 416	0	40 947 845	0	0
Issuance cost	-470 194		-618 499	0	-580 612
Cash flow from financing activities	**9 280 222**	**0**	**40 329 346**	**0**	**-580 612**
Cash flow for the period	**1 072 165**	**-12 499 850**	**19 485 248**	**-22 853 071**	**-40 507 714**
Cash and equivalents at the beginnging of period	31 527 550	43 739 810	13 274 287	54 110 725	54 110 725
Exchange rate differences in cash	-203 980	436 076	-363 800	418 382	-328 724
Cash and equivalents at the end of period	**32 395 735**	**31 676 036**	**32 395 735**	**31 676 036**	**13 274 287**

Key ratio Group

	Apr-Jun		Jan-Jun		Full Year
	2024	2023	2024	2023	2023
Net Sales, MSEK	-	-	-	-	-
Cash and equivalents, MSEK	32,4	31,7	32,4	31,7	13,3
Equity ratio, %	78	74	79	74	79
Quick asset ratio, %	227	785	124	785	124
Number of shares in the beginning of period	499 782 948	182 267 447	346 822 966	149 104 183	149 104 183
Average number of shares in the period	512 910 004	264 717 199	499 566 445	210 595 498	244 898 561
Number of shares in the end of period	597 287 105	277 470 338	597 287 105	277 470 338	282 269 454
Profit/Loss, MSEK	-11,2	-8,0	-20,2	-15,6	-135,5
Earnings per share, SEK	-0,02	-0,03	-0,04	-0,06	-0,48
Earnings per share after dilutions, SEK	-0,02	-0,03	-0,04	-0,06	-0,48

THE PARENT COMPANY'S FINANCIAL STATEMENTS

Income Statement, summary Parent company

Amount in SEK	Apr-Jun		Jan-Jun		Full Year
	2024	2023	2024	2023	2023
Operation income etc.					
Net Sales	0	0	0	0	0
Other income	1 037 985	1 120 559	2 126 481	2 179 866	4 449 564
Operating expenses					
Other external costs	-2 189 868	-2 510 234	-4 156 950	-4 753 693	-10 840 879
Personnel costs	-176 607	-97 755	-299 814	-223 223	-398 188
Write-down intangible assets	0		0		-113 300 014
Other operating expenses	-984	-21 805	-12 195	-30 090	-122 844
Total expenses	**-2 367 459**	**-2 629 794**	**-4 468 959**	**-5 007 006**	**-124 661 925**
Operating result	**-1 329 475**	**-1 509 235**	**-2 342 477**	**-2 827 141**	**-120 212 361**
Result from financial investments					
Write-down of investment in subsidiary	0	0	0	0	-33 454 609
Other interest income and similar items	81	73	2 179	154	537 886
Other interest expenses and similar items	0	0	0	0	-276
Total result from financial investments	**81**	**73**	**2 179**	**154**	**-32 917 000**
Net loss	**-1 329 394**	**-1 509 162**	**-2 340 299**	**-2 826 987**	**-153 129 361**

Balance Sheet, summary, Parent company

Amount in SEK	2024-06-30	2023-06-30	2023-12-31
ASSETS			
Subscribed capital unpaid	**0**	**0**	**31 197 429**
Fixed assets			
Capitalized expenditure on development work and similar work	1 835 958	115 135 972	1 835 958
Participation in group companies	68 767 661	68 767 661	68 767 661
Total fixed assets	*70 603 619*	*183 903 633*	*70 603 619*
Current assets			
Other receivables	324 083	253 657	339 616
Tax receivables	4 165	4 165	2 695
Receivables from group company	21 066 152	21 258 027	0
Prepaid expenses and accrued income	69 438	84 022	158 024
Cash and cash equivalents	25 653 676	24 578 687	9 268 148
Total current assets	*47 117 514*	*46 178 557*	*9 768 484*
Total assets	**117 721 133**	**230 082 190**	**111 569 531**
Equity			
Restricted equity	72 775 763	139 428 746	62 768 203
Profit or loss brought forward / Loss for the year	30 260 276	44 001 238	33 476 220
Total equity	*103 036 039*	*183 429 984*	*96 244 423*
Provisions			
Additional purchase price for subsidiaries	0	45 500 000	0
Total provisions	*0*	*45 500 000*	*0*
Current liabilities			
Accounts payables	502 369	356 522	1 464 970
Other liabilities	13 190 002	0	13 000 003
Accrued expenses and deferred income	992 723	795 685	860 135
Total current liabilities	*14 685 095*	*1 152 206*	*15 325 108*
Total equity and liabilities	**117 721 133**	**230 082 190**	**111 569 531**

Changes in shareholders equity, Parent company

	Restricted equity				Non restricted equity		
Amount in SEK	Share-capital	New share issue in progress	Statutory reserve	Reserve develop-ment cost	Share premium reserve	Profit/loss brought forward	Profit/loss for the year
Shareholders equity 2024-01-01	**34 682 296**	**15 038 855**	**13 047 052**	**0**	**224 179 241**	**-190 703 021**	**96 244 423**
Issue of new shares	25 046 414	-15 038 855			642 857		**10 650 416**
New share issue in progress					-1 518 501		**-1 518 501**
Loss for the period						-2 340 299	**-2 340 299**
Eget kapital 2024-06-30	**59 728 710**	**0**	**13 047 052**	**0**	**223 303 597**	**-193 043 319**	**103 036 039**

	Restricted equity				Non restricted equity		
Amount in SEK	Share-capital	New share issue in progress	Statutory reserve	Reserve develop-ment cost	Share premium reserve	Profit/loss brought for-ward	Profit/loss for the year
Shareholders equity 2023-01-01	**28 226 945**	**0**	**13 047 052**	**98 154 749**	**182 556 634**	**-135 728 409**	**186 256 971**
Issue of new shares	6 455 351				16 138 378		**22 593 729**
New share issue in progress		15 038 855			37 597 138		**52 635 993**
Issuance cost					-12 112 909		**-12 112 909**
Reserve development costs				-98 154 749		98 154 749	**0**
Loss for the peri-od						-153 129 361	**-153 129 361**
Shareholders equity 2023-12-31	**34 682 296**	**15 038 855**	**13 047 052**	**0**	**224 179 241**	**-190 703 021**	**96 244 423**

Cash flow statement, summary, Parent company

Amount in SEK	Apr-Jun		Jan-Jun		Full Year
	2024	2023	2024	2023	2023
OPERATING ACTIVITIES					
Profit after financial items	-1 329 394	-1 509 162	-2 340 299	-2 826 987	-153 129 361
Adjustment	-735	-735	-1 470	-1 470	113 300 014
Cashflow from operating activities before changes in working capital	*-1 330 129*	*-1 509 897*	*-2 341 769*	*-2 828 457*	*-39 829 347*
Cash flow from changes in working capital					
Changes in receivables	-9 831 927	-12 942 123	-20 962 034	-17 823 915	3 276 844
Changes in liablilites	23 224	-488 235	-640 014	-319 745	850 459
Total changes in working capital	*-9 808 703*	*-13 430 359*	*-21 602 048*	*-18 143 659*	*4 127 303*
Cash flow from operating activities	**-11 138 832**	**-14 940 256**	**-23 943 817**	**-20 972 116**	**-35 702 044**
FINANCING ACTIVITIES					
Share issue	9 750 416	0	40 947 845	0	0
Issuance cost	-470 104	0	-618 499	0	-580 612
Cash flow from financing activities	**9 280 312**	**0**	**40 329 346**	**0**	**-580 612**
Cash flow for the period	**-1 858 520**	**-14 940 256**	**16 385 529**	**-20 972 116**	**-36 282 656**
Cash and equivalents at the beginnging of period	27 512 196	39 518 942	9 268 148	45 550 803	45 550 804
Cash and equivalents at the end of period	**25 653 676**	**24 578 686**	**25 653 676**	**24 578 686**	**9 268 148**

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

For further information, please contact:
Prolight Diagnostics AB (publ)
E-mail: info@prolightdx.com
Telephone: +46 73 582 39 87
Website: www.prolightdx.com/en/